Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas
- PMID: 21358596
- PMCID: PMC3524735
- DOI: 10.12659/msm.881442
Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas
Abstract
Background: The tumor suppressor gene p53 is a key regulator of cell division and/or apoptosis. Survivin is a multifunctional member of the inhibitor of apoptosis family. Survivin and p53 represent diametrically opposed signals that influence the apoptotic pathway.
Material/methods: To determine the role of p53 and survivin in basal cell carcinoma (BCC), we evaluated the expression pattern of both proteins with regard to the percentage of positively immunostained tumor cells, the intensity of staining, and subcellular localization among 31 subjects with BCC.
Results: Overexpression of p53 protein was found in 28 of 31 cases (90.3%), whereas survivin accumulation was seen in 27 (87.1%). For p53, moderate and/or strong immunoreactivity was seen in 20 of 28 cases (71.4%), and 26 of 28 cases (92.9%) showed more than 25% reactive tumor cells. Nuclear p53 staining was detected in 23 of 28 cases (82.1%), whereas combined nuclear and cytoplasmic localization was found in only 5 of 28 cases (17.9%). Survivin revealed mild intensity of immunoreaction in 22 of 27 cases (71%), and 25 of 27 cases (92.6%) showed less than 25% labeled tumor cells. Combined nuclear and cytoplasmic survivin localization was present in 26 of 27 cases (96.3%). Statistically significant differences were detected in the assessed expression parameters between those proteins.
Conclusions: Our results suggest that overexpression of wild type p53 protein may suppress the expression of survivin and its antiapoptotic activity in BCC cells.
Figures

Similar articles
-
Expression profiles of p63, p53, survivin, and hTERT in skin tumors.J Cutan Pathol. 2004 Sep;31(8):544-9. doi: 10.1111/j.0303-6987.2004.00228.x. J Cutan Pathol. 2004. PMID: 15268709
-
Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line.J Dermatol Sci. 2016 Mar;81(3):182-91. doi: 10.1016/j.jdermsci.2015.12.011. Epub 2015 Dec 29. J Dermatol Sci. 2016. PMID: 26775629
-
Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.J Cutan Pathol. 2000 Apr;27(4):169-75. doi: 10.1034/j.1600-0560.2000.027004169.x. J Cutan Pathol. 2000. PMID: 10774937
-
Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.PLoS One. 2019 Apr 24;14(4):e0215537. doi: 10.1371/journal.pone.0215537. eCollection 2019. PLoS One. 2019. PMID: 31017970 Free PMC article.
-
p53 protein in aggressive and non-aggressive basal cell carcinoma.J Cutan Pathol. 1993 Oct;20(5):429-34. doi: 10.1111/j.1600-0560.1993.tb00666.x. J Cutan Pathol. 1993. PMID: 7507946
Cited by
-
BRAF inhibitor candidate molecule usnic acid might use both intrinsic and extrinsic pathways of apoptosis.Turk J Med Sci. 2024 Aug 9;54(5):1116-1126. doi: 10.55730/1300-0144.5890. eCollection 2024. Turk J Med Sci. 2024. PMID: 39473730 Free PMC article.
-
Genome-Wide Expression Difference of MicroRNAs in Basal Cell Carcinoma.J Immunol Res. 2021 Aug 4;2021:7223500. doi: 10.1155/2021/7223500. eCollection 2021. J Immunol Res. 2021. PMID: 34395634 Free PMC article.
-
Patterns of proliferation and apoptosis in different subtypes of basal cell carcinoma, adjacent epidermis, and recurrent forms.An Bras Dermatol. 2019 Jan-Feb;94(1):108-110. doi: 10.1590/abd1806-4841.20198165. An Bras Dermatol. 2019. PMID: 30726478 Free PMC article. No abstract available.
-
Whole‑genome identification and systematic analysis of lncRNA‑mRNA co‑expression profiles in patients with cutaneous basal cell carcinoma.Mol Med Rep. 2021 Sep;24(3):631. doi: 10.3892/mmr.2021.12270. Epub 2021 Jul 19. Mol Med Rep. 2021. PMID: 34278484 Free PMC article.
-
Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins.Molecules. 2021 Jun 9;26(12):3528. doi: 10.3390/molecules26123528. Molecules. 2021. PMID: 34207840 Free PMC article.
References
-
- Kastan MB, Onkyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304–11. - PubMed
-
- Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–22. - PubMed
-
- Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional Repression of the Anti-apoptotic survivin Gene by Wild Type p53. J Biol Chem. 2002;277:3247–57. - PubMed
-
- Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor supressor protein. Gene. 2000;242:15–29. - PubMed
-
- Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-supressor protein p53 by DNA-damaging agents. Oncogene. 1993;8:307–18. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous